Karyopharm Initiates Registration-Directed, Randomized Study Of Selinexor (KPT-330) In Older Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

“Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the initiation of its Phase 2 study of Selinexor (KPT-330) in patients 60 years of age or older with relapsed or refractory acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy and/or transplantation. This S elinexor in O lder P atients with R elapsed/Refractory A ML (SOPRA) study is a randomized trial of Selinexor, the company’s novel oral Selective Inhibitor of Nuclear Export (SINE) compound, versus physician’s choice, and will be conducted at approximately 40 sites worldwide including sites in the United States, Canada, Europe and Israel.”

Editor’s note: This story is about a clinical trial to test a potential new treatment for relapsed or refractory acute myelod leukemia (AML) in volunteer patients. The trial is testing whether a drug called Selinexor (aka KPT-330) is effective for patients 60 years of age or older who, for whatever reason, cannot be treated with intensive chemotherapy and/or transplantation. 2/3 of the participating patients will take Selinexor, and for comparison, 1/3 will receive a different standard treatment. The trial is randomized, meaning that patients cannot choose which treatment they receive.